incid
skin
soft
tissu
infect
ssti
due
resist
mdr
pathogen
continu
result
antibiot
use
increas
parallel
trend
exampl
studi
canada
demonstr
increas
physician
visit
ssti
associ
increas
antibiot
prescript
unfortun
increas
antibiot
use
becom
major
drive
forc
develop
resist
organ
undermin
staphylococcu
aureu
etiolog
agent
endem
caus
major
ssti
unit
grow
rate
aureu
mrsa
present
emerg
treatment
challeng
moreov
wherea
major
mrsa
infect
exponenti
increas
mrsa
sinc
late
lead
greater
social
financi
burden
result
pathogen
also
demonstr
emerg
resist
mani
antibiot
exampl
group
mdr
bacteria
refer
eskap
pathogen
enterococcu
faecali
aureu
klebsiella
pneumonia
acinetobact
baumannii
pseudomona
aeruginosa
enterobact
speci
appropri
name
escap
effect
varieti
antibacteri
drug
complic
ssti
ongo
crisi
warrant
develop
innov
therapeut
strategi
combat
mrsa
resist
microb
implic
ssti
sever
mechan
pathogen
overcom
antibiot
activ
resist
antibiot
occur
via
inher
resist
certain
speci
speci
produc
penicillinas
therefor
resist
antibiot
resist
also
occur
via
de
novo
mutat
acquisit
resist
gene
via
horizont
transfer
resist
mechan
includ
direct
remov
drug
intracellular
space
decreas
diffus
drug
via
modif
loss
porin
alter
upregul
drug
target
site
bacteri
enzym
drug
excess
antibiot
use
associ
emerg
select
antibiot
overus
misus
also
contribut
grow
problem
bacteri
nitric
oxid
diatom
gaseou
molecul
endogen
produc
among
properti
exhibit
broad
spectrum
antimicrobi
activ
antibiot
agent
exert
multipl
mechan
antimicrobi
action
limit
pathogen
abil
develop
resist
drug
advantag
reason
risk
bacteri
resist
innat
product
exogen
deliveri
minim
exhibit
multipl
mechan
antimicrobi
howev
util
clinic
set
restrict
highli
reactiv
lack
proper
vehicl
deliveri
varieti
exogen
sourc
develop
studi
antimicrobi
efficaci
limit
preclud
use
clinic
set
nanotechnolog
offer
platform
target
drug
deliveri
extens
research
conduct
evalu
efficaci
antibacteri
nanoparticl
np
broad
antimicrobi
properti
success
incorpor
np
offer
promis
solut
treatment
ssti
one
smallest
biolog
activ
act
virtual
everi
cell
lipophil
charact
low
molecular
weight
travers
physiolog
barrier
rel
eas
reach
target
addit
diffus
along
concentr
gradient
therefor
cross
cell
membran
without
need
transport
natur
yet
free
ga
highli
unstabl
oxygen
environ
spontan
react
oxygen
superoxid
form
reactiv
nitrogen
oxid
speci
rno
endogen
synthes
one
three
distinct
nitric
oxid
synthas
no
enzym
induc
oxid
arginin
citrullin
figur
two
no
isoform
constitut
also
known
cell
type
enzymat
identifi
neuron
no
nno
neuron
cell
endotheli
no
eno
endotheli
cell
eno
nno
mean
activ
tightli
regul
activ
enzym
produc
low
quantiti
short
time
small
quantiti
function
signal
induc
no
ino
origin
discov
known
express
mani
cell
ino
gener
larg
quantiti
fashion
induc
wide
array
stimul
includ
proinflammatori
bacteri
polysaccharid
figur
often
act
synergist
ino
play
varieti
import
physiolog
role
includ
blood
pressur
regul
neurotransmiss
inhibit
platelet
aggreg
immun
respons
wound
short
measur
order
second
biolog
impact
determin
primarili
rate
site
action
often
close
site
gener
rapidli
scaveng
hemoglobin
initi
multipl
cellular
signal
cascad
notabl
via
solubl
guanylyl
cyclas
sgc
pathway
paradigm
bind
sgc
caus
increas
cyclic
gmp
level
activ
protein
kinas
g
signal
cascad
lead
mani
downstream
effect
facilit
local
biolog
activ
vasodil
neurotransmitt
well
distant
impact
interact
mani
molecular
target
includ
protein
thiol
heme
nonhem
iron
tyrosyl
radic
protein
deoxynucleotid
react
glutathion
gsh
molecul
form
rsno
function
carrier
free
radic
gener
potent
nitrosyl
agent
capabl
signal
cellular
damag
peroxynitrit
presenc
effect
occur
higher
concentr
sinc
mention
rapidli
scaveng
physiolog
condit
rsno
protein
complex
nitrit
may
assist
long
distanc
transport
howev
actual
speci
liber
carrier
short
major
cutan
cell
type
includ
adipocyt
endotheli
cell
melanocyt
keratinocyt
fibroblast
langerhan
cell
neutrophil
macrophag
express
isoform
no
therefor
abl
gener
releas
broad
array
physiolog
keratinocyt
major
constitu
epidermi
express
three
no
isoform
produc
hydrogen
peroxid
respons
inflammatori
stimuli
like
act
one
chief
protect
mechan
skin
epidermi
constantli
expos
foreign
matter
organ
addit
synthesi
skin
surfac
may
also
regul
growth
cutan
commens
acid
skin
environ
reactiv
nitrogen
intermedi
form
nitrou
acid
dinitrogen
trioxid
peroxynitrit
may
serv
nonspecif
defens
mechan
cutan
addit
fine
regul
respons
also
exhibit
no
speci
wound
heal
one
exampl
fibroblast
found
dermi
key
regul
dermal
remodel
synthes
extracellular
matrix
collagen
fibrin
orchestr
mani
complex
step
wound
heal
fibroblast
express
eno
nno
express
inconsist
across
differ
cell
possibl
depend
cell
matur
due
widespread
distribut
help
regul
basic
physiolog
role
establish
maintain
blood
flow
protect
respons
invad
microorgan
ultraviolet
melanogenesi
develop
erythema
edema
set
sever
intrins
antimicrobi
properti
therefor
vital
bodi
innat
immun
respons
defens
invad
one
main
mechan
abil
gener
rno
via
spontan
reaction
oxygen
superoxid
rno
includ
peroxynitrit
rsno
nitrogen
dioxid
dinitrogen
trioxid
dinitrogen
tetroxid
rno
thought
exert
antimicrobi
effect
induc
nitros
oxid
stress
toxic
peroxynitrit
form
oxid
burst
macrophag
highli
reactiv
potenti
cytotox
rno
nitros
protein
thiol
modifi
amino
acid
residu
thu
inactiv
essenti
also
nitrosyl
metal
center
modifi
protein
function
deplet
intracellular
iron
store
event
ultim
block
essenti
microbi
rno
also
damag
microbi
dna
via
varieti
mechan
includ
direct
rno
interact
dna
inhibit
dna
repair
replic
increas
synthesi
genotox
mediat
alkyl
agent
also
induc
dna
strand
break
abas
site
among
also
implic
lipid
damag
peroxid
subsequ
disrupt
microbi
importantli
abil
execut
antimicrobi
properti
dictat
concentr
low
concentr
exert
antimicrobi
properti
act
potent
immunostimulatori
role
mediat
immun
cell
differenti
prolifer
apoptosi
cytokin
product
express
adhes
molecul
synthesi
deposit
extracellular
matrix
concentr
build
secondari
ino
activ
inher
antimicrobi
properti
come
import
ino
activ
combat
infect
demonstr
ino
knockout
mice
greater
suscept
herp
simplex
viru
infect
higher
frequenc
viral
reactiv
delay
viral
clearanc
dorsal
root
ganglia
compar
infect
heterozyg
ino
knockout
mice
also
suscept
dengu
viru
infect
found
significantli
higher
viral
load
greater
mortal
compar
wildtyp
similar
result
seen
mice
treat
ino
inhibitor
aminoguanidin
treat
mice
suscept
salmonella
typhimurium
infect
provid
less
feedback
inhibit
ino
compar
eno
nno
allow
bolu
product
high
level
thwart
microbi
varieti
method
deliveri
demonstr
antibacteri
effect
gaseou
gno
bactericid
aureu
mrsa
escherichia
coli
group
b
streptococcu
p
aeruginosa
vitro
studi
acidifi
nitrit
donor
demonstr
efficaci
p
burkholderia
aureu
propionibacterium
diazeniumdiol
bactericid
e
donor
demonstr
activ
p
serratia
enterobact
typhimurium
e
final
mice
fail
inhibit
replic
listeria
monocytogen
succumb
listeria
inocula
least
lower
lethal
wildtyp
demonstr
antivir
activ
via
varieti
differ
donor
molecul
snap
inhibit
viru
ebv
protein
synthesi
dna
snap
also
inhibit
sever
acut
respiratori
syndrom
coronaviru
replic
cycl
reduc
porcin
parvoviru
dna
protein
synthesi
replic
acidifi
nitrit
cream
demonstr
cure
rate
patient
treat
molluscum
evid
microglia
inhibit
toxoplasma
gondii
replic
effector
mechan
util
import
cerebr
murin
macrophag
mice
leishmania
prolifer
increas
synthesi
inde
surviv
leishmania
within
host
macrophag
depend
parasit
abil
inhibit
host
ino
express
zeina
et
success
treat
male
patient
cutan
leishmaniasi
topic
glyceryl
trinitr
exogen
donor
gsno
snac
demonstr
leishmanicid
activ
vitro
kill
parasit
includ
trypanosoma
cruzi
plasmodium
imped
growth
cryptococcu
competit
inhibitor
synthesi
ad
activ
murin
macrophag
vitro
product
cryptostat
activ
macrophag
donor
molecul
also
demonstr
antifung
activ
inhibit
growth
six
candida
liber
acidifi
sodium
nitrit
effect
candida
albican
trichophyton
mentagrophyt
trichophyton
final
probiot
patch
fungicid
mentagrophyt
ghaffari
et
design
gno
exposur
chamber
test
antimicrobi
efficaci
gno
common
clinic
pathogen
constant
exposur
ppm
gno
inhibit
p
aeruginosa
aureu
growth
gno
bactericid
gno
deliv
ppm
h
bactericid
varieti
clinic
relev
pathogen
includ
aureu
mrsa
e
coli
group
b
streptococcu
p
aeruginosa
c
gno
administ
intermitt
aureu
p
aeruginosa
e
coli
short
durat
high
dose
ppm
bactericid
effect
demonstr
compar
continu
gno
deliveri
howev
took
h
longer
achiev
furthermor
util
intermitt
gno
treatment
may
limit
vivo
time
treatment
may
permit
bacteri
replic
possibl
warrant
investig
efficaci
continu
gno
treatment
also
evalu
vivo
aureu
inocul
wound
new
zealand
white
rabbit
wound
treat
ppm
gno
h
day
three
consecut
day
treatment
caus
signific
reduct
wound
bacteri
although
effect
antimicrobi
gno
limit
expens
requir
deliveri
ga
tank
length
time
requir
treatment
requir
nonambul
therapi
potenti
toxic
host
cell
product
develop
furthermor
gno
best
candid
topic
antimicrobi
therapi
short
prevent
deliveri
deep
organ
donor
includ
nitroglycerin
isosorbid
dinitr
isosorbid
sodium
nitroprussid
long
use
treat
cardiovascular
diseas
pauciti
research
examin
potenti
donor
antimicrobi
although
two
report
indic
limit
antibacteri
biofilm
disrupt
organ
nitrat
limit
side
effect
tachyphylaxi
continu
prolong
use
sodium
nitroprussid
fear
side
effect
avail
altern
donor
easili
administ
caus
fewer
side
effect
decreas
likelihood
organ
donor
investig
antimicrobi
efficaci
acidifi
nitrit
cream
gener
via
reaction
acid
vitro
investig
addit
nitrit
increas
microbicid
activ
acid
solut
contain
common
cutan
pathogen
includ
aureu
p
acn
c
albican
rubrum
donor
also
effect
kill
p
aeruginosa
b
acidifi
nitrit
cream
demonstr
efficaci
human
studi
tinea
tinea
molluscum
cream
advantag
easili
appli
effect
sever
pathogen
howev
limit
ingredi
must
mix
togeth
immedi
prior
associ
skin
irrit
rsno
includ
varieti
donor
possess
moieti
bound
thiol
sulfhydryl
group
releas
bond
cleav
although
releas
occur
spontan
transpir
physiolog
condit
releas
induc
light
wavelength
nm
direct
reaction
ascorb
copper
addit
releas
rsno
particip
transnitrosyl
process
transfer
anoth
thiol
import
implic
skin
thiol
group
abund
stratum
two
rsno
see
figur
gsno
snac
evalu
antimicrobi
efficaci
demonstr
effect
inhibitori
bactericid
effect
p
aeruginosa
staphylococci
aureu
serratia
marcescen
e
aerogen
snac
greater
antimicrobi
activ
compar
gsno
clinic
isol
gsno
snac
also
activ
leishmania
major
leishmania
despit
demonstr
antimicrobi
efficaci
rsno
limit
util
treat
ssti
thiol
spontan
form
disulfid
bond
presenc
heat
water
requir
refriger
powder
readi
addit
light
heat
enzym
superoxid
dismutas
varieti
dehydrogenas
induc
prematur
releas
synthet
donor
easili
produc
via
reaction
varieti
differ
amin
nonoat
stabl
ambient
condit
releas
two
molar
equival
spontan
expos
aqueou
rate
releas
control
modul
variou
paramet
includ
ph
temperatur
structur
nucleophil
demonstr
higher
bactericid
activ
e
coli
compar
convent
z
amino
nonoat
inhibit
growth
six
candida
speci
synergist
use
concert
azol
antifung
nonoat
advantag
spontan
releas
biolog
milieu
predict
depend
easi
prepar
excel
shelf
structur
yet
format
methemoglobin
potenti
limit
use
well
risk
pulmonari
system
toxic
secondari
product
nonoat
exampl
byproduct
avail
less
toxic
donor
antimicrobi
efficaci
minim
nonoat
use
probiot
patch
simpl
cost
effect
method
gener
gno
effect
dose
exploit
metabol
activ
lactobacillu
fermentum
lactic
bacterium
lactic
acid
react
nitrit
salt
present
patch
produc
gno
patch
bactericid
e
coli
aureu
p
aeruginosa
mrsa
result
almost
complet
death
baumannii
also
fungicid
toward
mentagrophyt
patch
applic
wound
new
zealand
white
rabbit
caus
signific
decreas
wound
area
nonsignific
decreas
wound
bacteri
burden
compar
major
limit
system
fact
rate
gno
product
depend
activ
l
fermentum
patch
introduc
variabl
peak
synthesi
new
class
donor
consist
framework
metal
ion
bind
gno
store
exposur
rate
extent
releas
alter
modifi
pore
size
metal
ion
within
advantag
stabil
larg
storag
capac
modifi
rate
zeolit
effect
mssa
mrsa
p
aeruginosa
c
among
investig
necessari
elucid
zeolit
antimicrobi
properti
potenti
util
treatment
despit
efficaci
antimicrobi
activ
donor
mani
limit
includ
instabl
skin
releas
low
inconsist
short
durat
nanoparticul
platform
repres
uniqu
way
circumv
limit
friedman
et
develop
hybrid
hydrogelglass
composit
nanoparticl
encapsul
sodium
nitrit
thermal
reduc
within
polymer
platform
base
establish
made
either
tetramethoxysilan
tmo
tetraethoxysilan
teo
refer
transit
system
liquid
sol
solid
gel
capabl
trap
protein
larg
molecul
yet
remain
porou
smaller
molecul
like
limit
drug
deliveri
capabl
overcom
limit
minim
poros
sugar
polysaccharid
like
chitosan
ad
synthesi
essenti
plug
result
glassi
properti
also
benefit
matrix
promot
thermal
reduct
nitrit
well
retent
sustain
final
formul
store
powder
form
remain
trap
matrix
dri
permit
easi
storag
upon
exposur
aqueou
environ
releas
initi
np
swell
take
rate
total
quantiti
releas
modifi
alter
synthesi
step
chang
concentr
nitrit
polyethylen
glycol
peg
molecular
weight
andor
exampl
util
larger
peg
increas
pore
size
allow
rapid
releas
pattern
wherea
made
smaller
peg
demonstr
slower
sustain
releas
time
minim
toxic
treat
human
lung
fibroblast
reconstitut
human
epidermi
human
lung
fibroblast
treat
vitro
demonstr
minim
toxic
compar
cultur
media
control
particl
suggest
therapeut
agent
safe
topic
furthermor
clinic
advers
event
report
murin
model
infect
treat
eas
synthesi
storag
administr
control
releas
make
attract
broad
rang
clinic
scenario
includ
treatment
ssti
shin
et
prepar
synthet
silica
np
via
process
drug
deliveri
potenti
silica
attract
chemic
structur
versatil
well
fact
teo
tmo
combin
aminoalkoxysilan
ethanol
methanol
water
ammonia
amin
function
group
convert
nonoat
technolog
advantag
two
reason
first
capabl
store
larg
quantiti
second
np
size
nm
h
releas
kinet
h
alter
modif
synthet
process
temperatur
ph
type
concentr
hybrid
develop
friedman
et
al
exhibit
vitro
efficaci
varieti
bacteria
includ
streptococcu
e
k
e
coli
p
nanoparticl
platform
also
effect
c
albican
silica
np
demonstr
greater
bactericid
efficaci
p
aeruginosa
compar
nonencapsul
small
molecul
donor
prolino
cytotox
studi
mous
fibroblast
confirm
silica
np
nontox
mammalian
cell
concentr
capabl
kill
p
aeruginosa
prolino
toxic
host
cell
bactericid
smaller
silica
np
nm
effect
kill
p
aeruginosa
compar
larger
np
ident
releas
importantli
sever
bacteri
speci
test
mssa
mrsa
epidermidi
e
coli
p
aeruginosa
unabl
develop
resist
silica
np
multipl
exposur
coloni
np
effect
kill
pathogen
demonstr
greater
kill
rate
biofilm
cell
p
aeruginosa
e
coli
aureu
epidermidi
c
albican
greatest
efficaci
p
aeruginosa
e
coli
biofilm
repres
seriou
therapeut
impedi
given
abil
block
drug
penetr
well
permit
transfer
resist
gene
commun
hypothes
eas
diffus
across
biolog
membran
may
allow
enhanc
penetr
biofilm
compar
tradit
therefor
platform
may
one
avenu
address
friedman
et
al
hybrid
investig
multipl
murin
infect
model
appli
murin
model
wound
wound
clinic
demonstr
acceler
wound
closur
figur
significantli
lower
bacteri
burden
compar
control
histolog
examin
wound
tissu
show
infect
wound
treat
less
inflamm
organ
granul
tissu
less
destruct
chang
dermal
architectur
analog
studi
appli
murin
model
mdr
excision
wound
similar
effect
wound
significantli
increas
rate
wound
heal
figur
even
wound
decreas
wound
bacteri
load
inhibit
collagen
baumannii
increasingli
common
etiolog
agent
nosocomi
infect
also
implic
wound
infect
soldier
deploy
iraq
afghanistan
resist
mani
antibiot
complic
treatment
infect
therefor
success
topic
treatment
baumannii
wound
infect
promis
hybrid
found
effect
treat
burn
wound
infect
c
albican
treat
wound
heal
significantli
faster
control
wound
figur
significantli
lower
fungal
burden
histolog
analysi
demonstr
less
suppur
inflamm
fibrin
deposit
group
associ
increas
collagen
content
interestingli
mice
control
group
clinic
demonstr
fungal
transmiss
burn
site
back
paw
indic
erythema
white
macer
find
highlight
import
quickli
effect
treat
infect
elimin
potenti
mrsa
common
pathogen
also
associ
deeper
bacteri
infect
intraderm
intramuscular
abscess
charact
poor
perfus
abscess
often
difficult
treat
convent
antibiot
light
friedman
et
al
hybrid
evalu
treatment
clinic
entiti
murin
model
topic
intraderm
applic
significantli
reduc
intraderm
abscess
area
figur
bacteri
burden
treatment
result
improv
preserv
dermal
subcutan
architectur
less
inflamm
bacteri
presenc
histolog
mous
model
intramuscular
abscess
topic
intralesion
administr
hybrid
also
significantli
decreas
mrsa
burden
within
muscl
compar
control
mice
anim
treat
system
vancomycin
commonli
use
system
antibiot
mrsa
ssti
mice
demonstr
clinic
acceler
abscess
clearanc
base
visual
decreas
abscess
size
purul
compar
treatment
group
figur
histolog
intralesion
administr
result
less
muscl
necrosi
granulomat
inflamm
decreas
bacteri
load
compar
control
mice
vancomycin
signific
impact
intramuscular
abscess
compar
untreat
outcom
extent
anim
treat
rsno
compound
gener
reaction
thiol
gsno
function
donor
transfer
nitrosonium
ion
thiol
moieti
protein
process
call
tran
gsno
main
activ
nitros
cellular
protein
gsno
revers
block
enzym
protein
function
disabl
key
pathogen
machineri
counteract
threat
cell
viabil
result
nitros
critic
cellular
element
bacteria
employ
gsno
nitroreductas
also
regener
gsno
serv
stabl
reservoir
donat
advantag
compar
half
live
measur
minut
hour
compar
free
addit
describ
gsno
potent
nitros
agent
confer
antimicrobi
activ
threaten
microorgan
viabil
fact
antimicrobi
efficaci
gsno
solut
e
coli
previous
elucid
gsno
impact
bacteri
growth
surviv
friedman
et
al
evalu
abil
hybrid
gener
gsno
presenc
combin
gsh
form
gsno
also
produc
signific
concentr
gsno
extend
time
period
greater
h
like
secondari
control
sustain
releas
correspond
steadi
gsno
format
mixtur
gsh
significantli
inhibit
growth
andor
surviv
e
coli
k
pneumonia
p
aeruginosa
compar
control
alon
k
pneumonia
resist
formul
wherea
p
aeruginosa
suscept
exhibit
growth
given
static
cidal
activ
gsno
vitro
efficaci
platform
evalu
previous
describ
excision
wound
model
infect
mdr
clinic
isol
p
aeruginosa
wound
treat
gsh
exhibit
significantli
acceler
wound
closur
clinic
histolog
well
lower
bacteri
burden
base
tissu
cultur
compar
control
wound
find
gsh
effect
correl
vitro
data
p
aeruginosa
may
sensit
nitrosothiol
oppos
vitro
vivo
set
gsh
greater
antimicrobi
activ
compar
alon
may
gsno
stabl
reservoir
potent
nitros
agent
capabl
render
microbi
protein
inact
addit
gsno
activ
taken
microbi
system
usual
function
import
gsh
enabl
gsno
reach
intracellular
bacteri
target
access
result
promis
highlight
versatil
applic
wide
array
clinic
rise
pathogen
resist
antimicrobi
armamentarium
econom
burden
infect
due
mdr
organ
underscor
need
develop
innov
therapeut
circumv
nitric
oxid
attract
approach
combat
medic
epidem
due
multipl
mechan
static
cidal
activ
broad
rang
organ
small
size
hydrophob
natur
enabl
rapidli
travers
bacteri
membran
significantli
impact
interfer
cell
function
importantli
shown
multipl
bacteri
speci
develop
resist
exogen
even
multipl
exposur
cell
therefor
unlik
resist
would
develop
would
requir
multipl
mutat
occur
despit
proven
antimicrobi
efficaci
varieti
donor
mani
limit
preclud
use
clinic
set
recent
advanc
deliveri
particularli
use
nanotechnolog
promis
eas
nanoparticl
product
storag
administr
modul
render
attract
therapeut
modal
ssti
design
local
applic
minim
risk
system
toxic
associ
tradit
system
administ
antibiot
proven
vitro
vivo
antimicrobi
efficaci
provid
evid
nanotechnolog
potenti
treat
ssti
caus
varieti
pathogen
includ
resist
tradit
antibiot
therapeut
use
combat
andor
disast
situat
special
medic
care
technolog
readili
avail
would
ideal
given
breadth
physiolog
importantli
antimicrobi
innov
approach
promis
solut
treatment
ssti
set
escal
bacteri
resist
